Man Group
KRYS icon

Man Group’s Krystal Biotech KRYS Stock Holding History

Man Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,088
Closed -$369K – 2377
2025
Q3 		$369K Sell
2,088
-28,393
-93% -$4.25M ﹤0.01% 1945
2025
Q2 		$4.19M Buy
+30,481
New +$4.48M 0.01% 1125
2024
Q4 		– Sell
-27,939
Closed -$5.09M – 2094
2024
Q3 		$5.09M Sell
27,939
-41,311
-60% -$7.97M 0.01% 1019
2024
Q2 		$12.7M Sell
69,250
-26,608
-28% -$4.47M 0.03% 596
2024
Q1 		$17.1M Buy
95,858
+45,022
+89% +$6.25M 0.04% 483
2023
Q4 		$6.31M Buy
+50,836
New +$5.64M 0.02% 852

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's KRYS Position: Q4 2025 in Review

Man Group sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 2,088 shares — an estimated $369K sold.

Man Group first reported a position in KRYS in Q4 2023 and held it in 6 quarters. The position peaked at $17.1M in Q1 2024. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Man Group reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • Man Group sold 2,088 Krystal Biotech shares in Q4 2025, an estimated $369K.
  • Man Group first reported a position in Krystal Biotech in Q4 2023 and held it in 6 quarters.
  • Man Group's Krystal Biotech position peaked at $17.1M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Man Group's 13F filing for Q4 2025, filed 17 Feb 2026.